NEW YORK - Goldman Sachs & Co (NYSE:GS). LLC disclosed their recent dealings in shares of Mural Oncology PLC, a pharmaceutical company, as per the requirements of the Irish Takeover Panel Act of 1997. On Tuesday, the investment bank engaged in transactions involving Mural Oncology’s USD 0.01 ordinary shares.
According to the disclosure, Goldman Sachs has both long and short positions in Mural Oncology, with 180,343 shares (1.04%) held long and 183,668 shares (1.06%) held short. Additionally, the bank conducted a sale of 3 Mural Oncology shares at a price of $2.67 per unit.
The dealings come amidst no publicly announced offers or takeovers involving Mural Oncology, suggesting Goldman Sachs’ trading activities are part of its routine investment operations. The bank confirmed that there are no agreements, arrangements, or understandings related to the voting rights of any relevant securities under any options or derivatives.
Furthermore, Goldman Sachs has purchased a swap derivative, with an expiry date of July 8, 2025, relating to one relevant security at an exercise price of $0.00, indicating a potential interest in future price movements of Mural Oncology’s shares.
The financial details of these transactions and positions are based on a press release statement and reflect Goldman Sachs’ investment strategies and market activities regarding Mural Oncology. It remains to be seen how these dealings will influence the investment bank’s portfolio and the pharmaceutical company’s stock performance in the future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.